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Abstract
Background
Colorectal cancer (CRC) is a life-threatening complication of ulcerative colitis (UC), and
patients are routinely screened for the development of precancerous lesions (dysplasia).
However, rates of CRC development in patients with confirmed low-grade dysplasia vary
widely between studies, suggesting a large degree of heterogeneity between these lesions
that is not detectable macroscopically. A better understanding of the underlying molecular
changes that occur in dysplasia will help to identify lesions at higher risk of malignancy.
MicroRNAs (miRNAs) post-transcriptionally regulate protein expression and cell-signalling
networks. Aberrant miRNA expression is a feature of sporadic CRC but much less is known
about the changes that occur in dysplasia and in UC.
Methods
Comprehensive microRNA profiling was performed on RNA extracted from UC dysplastic
lesions (n = 7) and UC controls (n = 10). The expression of miRNAs in UC post inflammatory
polyps (n = 7) was also assessed. Candidate miRNAs were further validated by qPCR, and
miRNA in situ hybridization. Serum levels of miRNAs were also assessed with a view to
identification of non-invasive biomarkers of dysplasia.
Results
UC dysplasia was associated with a shift in miRNA expression profiles that was not seen
in inflammatory polyps. In particular, levels of miR-200b-3p were increased in dysplasia,
and this miRNA was localised to epithelial cells in dysplastic lesions and in UC cancers. No
changes in miRNA levels were detected in the serum.
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Conclusion
UC-Dysplasia is linked to altered miRNA expression in the mucosa and elevated miR-200b-
3p levels.
Introduction
Inflammatory bowel diseases (IBD), which include ulcerative colitis (UC), are characterised by
uncontrolled intestinal inflammation. Colorectal cancer (CRC) is a life-threatening complica-
tion of UC, and UC patients are estimated to be at a 2.4 fold increased risk of CRC relative to
the general population.[1] The risk of CRC in UC patients increases considerably with duration
and extent of active inflammation, diagnosis at a younger age, concomitant primary sclerosing
cholangitis (PSC) and family history of CRC.[2,3] Relative to sporadic CRC, UC associated
CRC (UC-CRC) is linked to an earlier age of onset and higher rates of mortality; in one study,
59% of UC-CRC patients had died at 5-years of follow-up.[3]
Given the increased risk of UC-CRC, it is necessary to screen UC patients for the develop-
ment of precancerous lesions (dysplasia), with periodic chromoendoscopies starting 8–10
years after the first appearance of colitis-associated symptoms.[4,5] During surveillance proce-
dures, targeted biopsies are collected from suspect lesions and assessed by pathologists. The
presence of dysplasia is then used to guide and inform the subsequent clinical management of
the patient: for low-grade dysplasia (LGD) on flat mucosa it is advisable to reduce the interval
between surveillance colonoscopies, in the case of high-grade dysplasia (HGD) colectomy is
indicated.[4,5]
UC-associated post-inflammatory polyps (UC-IPs) (pseudopolyps) are raised areas of
inflamed mucosa or granulation tissue seen after intestinal mucosal recovery from inflamma-
tory damage. A history of UC-IP may be an indication of the severity of prior inflammation.
Current endoscopic surveillance programmes do not consider UC-IPs per se important clini-
cally and their recording may well be incomplete. Yet, a correlation between the presence of
colonic UC-IPs and increased risk of CRC has been proposed.[6–8] However, it remains to be
determined whether the link between UC-IPs and CRC is indirect or whether UC-IPs show
any features or changes in gene expression that might be associated with an increased risk of
malignancy.
The molecular mechanisms that lead to cancer from LGD in UC are poorly understood,
and rates of UC-CRC occurrence in patients with diagnosed LGD vary widely between studies
0–54%;[9–14] current estimates are that 19% of patients with a diagnosis of LGD develop
HGD or cancer.[15] This variation in outcomes probably reflects the fact that although LGD is
treated as a single entity it encompasses a range of underlying molecular changes which cannot
be distinguished macroscopically or histologically. Hence there is a significant clinical need for
molecular biomarkers to identify those dysplastic lesions that are at high risk of neoplastic pro-
gression and malignancy.
MicroRNAs (miRNAs) are small non-coding RNAs that inhibit protein translation by
binding to complementary sequences in the 3’UTR of target mRNAs. Each miRNA is pre-
dicted to bind to multiple potential mRNAs targets and thereby alter signalling pathways
within cells. MiRNAs have important roles in development and disease and have attracted par-
ticular attention for their role in cancer and IBD, and for their potential use as biomarkers and
therapeutic targets.[16] A role for miRNAs in sporadic CRC has been established.[17] How-
ever, far less is known about their function in UC-CRC and dysplasia with only two studies
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reported assessing patients with both UC and CD.[18,19] The techniques used and the clinical
characteristics of the specimens analysed also differ between studies. Moreover, because of the
low frequency of IBD-dysplasia the cohorts analysed are relatively small and the result requires
independent validation.[18,19]
In order to address the role of miRNAs in UC-dysplasia, we have determined miRNA
expression in a cohort of UC patients with and without dysplasia, using samples collected
from IBD surveillance centres across the UK. We have also compared miRNAs identified in
our study of UC with findings in the published literature on IBD-dysplasia. In addition, we
provide the first comprehensive analysis of miRNAs in UC-IPs and compare changes in
miRNA profiles between these polyps and UC controls. As miRNAs are also exported in the
wider circulation, the potential to utilise miRNAs as non-invasive biomarkers of UC-Dysplasia
(UC-DYS) was also explored in a proof-of-principle study.
Materials and methods
Ethics statement and patient selection
Ethics were obtained to recruit patients from multiple hospitals in UK (East London and The
City Research Ethics Committee 1, REC 09/H0703/116; UKCRN ID 8099). Inclusion criteria
in the study included a diagnosis of UC and enrolment in a surveillance programme. Patients
gave written informed consent on forms approved by the Ethics committee and were recruited
between 2010 and 2014.
The clinical and endoscopic disease activity was recorded for each patient, using the Mayo
score.[20] UC phenotype was classified according to Montreal criteria.[21] Further clinical
characteristics were also recorded, including age, ethnicity, disease duration, smoking habit,
medications, adherence to therapy, family history of colon cancer, concomitant diseases and
previous history of dysplasia.
Collection and selection of samples for microRNA analysis
Multiple biopsies were collected from 5 sites throughout the bowel during routine endoscopy
for histopathology and miRNA analysis. Biopsies for miRNA analysis were stored in RNAlater
at -80˚. The local pathologist assessed biopsies taken for histopathology. The resulting pathol-
ogy reports were used to classify the biopsies taken from the same site and stored in RNAlater
into those with and without dysplasia, and with and without evidence of histological inflam-
mation, (neutrophil infiltration of the epithelium). A peripheral blood sample was also col-
lected and centrifuged to obtain serum, and stored at -80˚C until further experiments.
To reduce possible confounding factors, samples from patients with coexisting primary
sclerosing cholangitis, previous history of dysplasia or CRC and colitis limited to the left-sided
colon or to the rectum were excluded from this study. Those samples used here were from
patients with pancolitis (E3 Montreal).
Tissue miRNA arrays
Biopsies stored in RNA later were homogenised in 700μL Qiazol, and RNA extractions were
performed using the miRNAesy Kit (Qiagen, UK) as per the manufacturer’s instructions. The
resultant RNA was sent to Exiqon (Denmark) for miRNA profiling using the miRCURY
LNA™ microRNA Array (7th Gen). The quantified signals were background corrected and
normalized using the quantile normalization method. The normalised data was then log2
transformed prior to statistical analysis.
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Serum miRNA arrays
Serum samples were sent to Exiqon (Denmark) and RNA extracted and analysed by qPCR
using miRCURY LNATM Universal RT microRNA PCR Human panel I+II. Samples were run
in two batches, and each batch contained UC controls and UC-dysplasia samples (batch one:
n = 5 and n = 3, respectively; batch two: n = 5 and n = 5, respectively). The data normalisation
was performed based on the average of the assays detected in all samples in each batch respec-
tively, and the normalised data log2 transformed. The data for each batch was then median-cen-
tred and combined prior to statistical analysis to account for ‘batch’ effects. Finally, miRNAs
were filtered to include only miRNAs that were detected above the background threshold in all
samples tested. The aim was to ensure that only robustly expressed miRNAs were considered.
MiRNA qPCR validation
A select number of miRNAs were evaluated by qPCR using the miScript primer assays (S1
Table). For qPCR analysis 1000 ng of RNA was reversed transcribed using the miScript II RT
Kit (Qiagen) and the miScript HighSpec buffer. The resultant cDNA was then diluted 10-fold
prior to qPCR analysis using the miScript miRNA quantification system (Qiagen). Each reac-
tion was performed in duplicate and melt curves performed to ensure a single PCR product
was synthesised. The resultant cycle threshold values (Ct’s) were exported into Excel, dupli-
cates were averaged, and data normalised to the geometric mean of RNU6 and SNORD42b,
two stably expressed small non-coding RNAs. The normalised expression values were then
log2 transformed to equalise variance prior to statistical analysis.
microRNA in situ hybridization
The levels of miR-200b-3p and miR-21-5p were investigated using miRNA in situ hybridization
(ISH) technology (Exiqon, Denmark) in formalin fixed paraffin embedded (FFPE) tissue taken
from the colon of UC patients. All blocks were obtained from the Royal London Pathology
archives, and 4 μm sections were cut under RNAse-free conditions. Prior to staining sections
were baked at 65˚C for 10 mins before deparaffinising in xylene for 10 mins and hydrating
through graded alcohols to RNAse-free H2O. Sections were digested with 10ug/ml proteinase K
in PBS at 37˚C for 30 minutes, washed in RNAse-free H2O and dehydrated. Sections were then
incubated with Double-DIG (digoxigenin) labelled Locked Nucleic Acid (LNA) ISH probes (60
nM, Exiqon) for miR-200b-3p (619853–360), miR-21-5p (619870–360) or a scrambled negative
control (699004–360) at 56˚C for 2 hours before a series of stringency washes and staining per-
formed as given previously.[22] A clinical pathologist [RF] at the Royal London Hospital con-
firmed positive staining and reviewed all slides.
Statistical analyses
Unsupervised principal component analysis (PCA) of miRNA levels in UC controls, UC-DYS
and UC-IPs was performed to explore natural grouping in the data using Solo software (Eigen-
vector, USA). The software’s proprietary algorithms were used to exclude miRNAs with exces-
sive missing values and replace any further missing values in the remaining data. The PCA was
carried out on the covariance matrix using the log2 transformed array data. Three components
were fitted to the model and these were sufficient to separate UC controls from UC dysplasia.
To identify individual differentially expressed miRNAs, the array data (both tissue and
serum) were analysed using the ‘Significance Analysis of Microarrays’ package in R. Missing
values were compensated for using the K-Nearest Neighbours Imputer algorithm, and the
number of neighbours set to 6. The log2 transformed data were median-centred, and a two-
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class unpaired analysis was performed with 1000 permutations. A significance cut-off was set
using a delta value of 0.5 and a 2-fold minimum change. Under these stringent cut-offs the
estimated false discovery rate was 0.00%.
For the qPCR validation analysis a two-way analysis of variance (ANOVA) test was used to
explore the relationship between miRNAs in dysplasia and inflammation, each modelled as
independent discrete factors. Post-hoc analyses were then performed to identify difference
between groups with alpha adjusted for multiple testing using the Bonferroni criterion.
In silico identification of microRNA targets
Experimentally validated target genes for candidate miRNAs were obtained using miRTar-
Base,[23] which contains targets that have been validated by reporter assays, western blot,
qPCR, microarray and next-generation sequencing experiments. miRNA-target interactions
were also investigated based on the collective information of functional studies of miRNAs in
the database. To bioinformatically predict target genes based on the miRNA seed sequence,
two predictive algorithms were used, TargetScan as well as miRDB.[24,25]
To investigate the influence of candidate miRNA transcript levels in UC dysplasia, we interro-
gated the gene signatures obtained by cDNA microarrays in 4 UC patients without dysplasia and
11 UC patients harbouring remote neoplasia.[26] To obtain a list of all differentially expressed
genes across the two groups, the microarray datasets were obtained from the GEO repository
(accession number GSE37283) and analysed with GEO2R, a web-based application that performs
comparisons between groups on the original submitter-supplied microarray datasets. GEO2R uses
the GEOquery and limma R packages from the Bioconductor project. For consistency, to identify
differentially expressed genes, we applied the following thresholds: adjusted p-value< 0.05 (based
on the Benjamini & Hochberg false discovery rate method) and |log2(fold-change)|> 1.
Results
Study design and biopsy characteristic
To interrogate miRNA profiles in UC-DYS lesions, RNA extracted from biopsies collected
during routine surveillance endoscopies with and without evidence of dysplasia was analysed
(n = 10 and n = 7, UC controls and UC-DYS, respectively); the clinical characteristics of
patients from whom a UC dysplasia sample was taken is given in Table 1. For the array, the
cohort was predominantly White (6/7), the median age was 73 years, and all patients had a his-
tory of pancolitis (E3 disease). Biopsies were taken from sites of dysplasia throughout the
colon: 2 from the ascending colon, 2 from the transverse colon, 2 from sigmoid colon and 1
Table 1. Characteristics of ulcerative colitic patients from whom a dysplasia specimen was obtained. All were from patients classified as Montreal
E3.
Pt Gender Age Ethnicity Disease duration (years) Smoking habit Dysplasia site Active (Y/N) 5ASA (Y/N) Tissue analysed by array
1 F 73 White 42 Never Sigmoid Y Y Y
2 M 75 Indian 28 Never Transv N Y Y
3 F 55 White 20 Never Ascend Y Y Y
4 F 59 White 15 Never Transv Y Y Y
5 F 73 White 34 Never Rectum N Y Y
6 F 62 White 30 Never Sigmoid N Y Y
7 M 81 White 32 Former Ascend N Y Y
8 M 69 White 32 Never Transv Y — N
9 M 50 White 37 Never Caecum Y Y N
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from the rectum. Of these, 6/7 (86%) was classified as LGD and 1/7 had HGD; 3/7 biopsies
also had evidence of histological inflammation. RNA isolated from UC-IPs (n = 7) was also
analysed (S2 Table).
To identify miRNAs associated with UC-DYS that were independent of intestinal location
and disease activity, control biopsies were pooled from a number of UC patients with respect
to presence or absence of histological inflammation (active and inactive) and the five-biopsy
sites (ascending colon, transverse colon, descending colon, caecum, or rectum). This gave a
final 10 control samples. RNA isolated from UC-IPs (n = 7) was also analysed to determine
whether these possessed similar changes in gene expression to dysplasia specimens.
Identification of miRNAs associated with dysplasia in ulcerative colitis
The expression levels of 1899 miRNAs were assessed by array, of which 1240 (65%) were not
detected above the background threshold levels in any of the 24 samples analysed and there-
fore excluded. One control sample (an active biopsy from the caecum) was further excluded
on the basis of a lower call rate than the remaining samples (S1 Fig). To explore natural group-
ing within the data unsupervised principal component analysis (PCA) was performed. For
PCA, miRNAs with excessive missing values were excluded (a total of 258), and only the
remaining 401 miRNAs were considered (S1 Fig). The resultant PCA model demonstrated
some separation of UC-DYS from control samples, suggesting that UC-DYS is associated with
a shift in miRNA expression profiles. Control samples were separated completely from dyspla-
sia samples within the first three principal components with the sole exception of one sample,
an active rectal biopsy (Fig 1A).
Fig 1. Altered miRNA profiles in ulcerative colitis associated-dysplasia. (A) Principal component
analysis of UC-controls, UC-Dysplasias and UC-inflammatory polyps, showing natural groupings within the
data along the first three principal components. (B) Heatmap of miRNAs identified by permutation analysis as
differentially expressed in UC-dysplasia relative to UC-controls. The data are presented as Log2 fold change
in UC-dysplasia relative to UC-controls, and the y-axis is ranked accordingly.
https://doi.org/10.1371/journal.pone.0173664.g001
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To identify differentially expressed individual miRNAs the array data was analysed using
‘Significance Analysis of Microarrays’ software with an estimated false discovery rate of 0%
and a fold change >2 set as stringent cut-off values for significance. This analysis identified 22
miRNAs that were upregulated in dysplasia and 8 miRNAs that were present at lower levels in
UC-DYS lesions (Table 2; Fig 1B). A number of the miRNAs identified had been previously
linked to IBD-DYS, including miR-200b-3p, miR-200a-3p, miR-192-5p, and miR-155-5p13.
Previously reported associations between miR-21-5p12 were also confirmed (S2B Fig);
reported difference in miR-31 in IBD-dysplasia[19] could not be fully assessed here as miR-
31-5p expression was only detected in 2 of the 24 samples analysed by array. However, it is
noteworthy that both biopsies where miR-31-5p levels were detected above the background
threshold were dysplastic (S2D Fig).
Changes in miRNA profiles in post inflammatory polyps
To determine whether the miRNA profiles of UC-IPs resembled UC-DYS specimens or not,
the UC-IP miRNA expression changes were fitted to the PCA model. Interestingly, UC-IPs
Table 2. miRNAs associated with ulcerative colitis-dysplasia.















miR-200a-3p 2.3164 <0.001 Up regulated in IBD-dysplasia[19]
miR-23b-3p 2.5008 <0.001
miR-192-5p 2.1055 <0.001 Up regulated in IBD-dysplasia[19]
miR-194-5p 2.0351 <0.001 Up regulated in IBD-dysplasia[19]
miR-21-5p 2.0956 <0.001 Up regulated in IBD-dysplasia[18]
miR-24-3p 2.0126 <0.001
miR-29b-3p 2.0203 <0.001
miR-142-3p 2.0688 <0.001 Down regulated in IBD-dysplasia[19]
miR-552 0.4573 <0.001 Up regulated in IBD-dysplasia[19]








The miR-200 family in ulcerative colitis dysplasia
PLOS ONE | https://doi.org/10.1371/journal.pone.0173664 March 13, 2017 7 / 17
appeared to form an intermediate group, with some samples clustering with controls and
other samples with the UC-DYS specimens (Fig 1A). However, relative to controls, in terms of
absolute differences in expression, there were only two miRNAs with a fold change>2 at a
FDR of 0.00% in UC-IPs using the SAM software: miR-144-3p was increased in UC-IPs (2.017
fold, q<0.001) and miR-4795-3p was reduced (0.456 fold, q<0.001). There was no overlap
between miRNAs that marked UC-IPs and those that were associated with UC-DYS.
qPCR validation of miRNA changes in dysplasia
To confirm the findings of the array, qPCR validation was performed for 7 miRNAs upregu-
lated and 1 miRNAs down-regulated in UC-DYS in the array. The validation cohort was
expanded in number, but included samples previously analysed by array and therefore does
not represent a wholly independent cohort (UC-DYS n = 10 and UC controls n = 16); where
multiple biopsies were taken from individual control UC patients they were averaged with
respect to disease activity to avoid pseudo-replication of the data. There were no significant
differences between UC-DYS and UC controls in our initial analysis (t-test, S3 Table).
One potential confounding factor in this analysis is a change in the proportions of UC-DYS
samples with active disease analysed in the validation cohort compared to the array cohort: 3/4
in the array cohort vs. 7/11 in the validation cohort. Hence a two-way ANOVA was performed
to investigate the relationship between dysplasia, disease activity and miRNAs levels, followed
by post-hoc comparisons of groups. This demonstrated that for 3 of the miRNAs tested (miR-
200b-3p, miR-451a, and miR-27b), there was a significant interaction term for UC-DYS and
disease activity (Table 3). A subsequent post-hoc test demonstrated that miR-200b-3p was signifi-
cantly up-regulated (fold change>2) in UC-DYS specimens in the absence of histological in-
flammation relative to inactive controls in line with the results of the array (p = 0.033). However,
as disease activity tended to supress miR-200b-3p levels in the UC-DYS group (p = 0.010), dys-
plasia–associated differences in expression were not seen on a background of histological inflam-
mation (Fig 2A). Conversely, and in contrast to the array, a significant reduction in miR-27b was
observed in UC-DYS relative to controls on an inactive background (p = 0.016); in the UC-DYS
group histological inflammation was associated with higher miR-27b levels (p = 0.015) (Fig 2B).
No significant differences in miR-451a were identified in the post-hoc comparisons of the groups
once alpha was adjusted for multiple testing (Fig 2C). In contrast to previous studies miR-21-5p
showed a stronger association with disease activity than with dysplasia (Fig 2D).
Table 3. Two-way analysis of variance of miRNA levels in ulcerative colitis-associated dysplasia and controls.
miRNA ID Two-way ANOVA Posthoc comparisons




and controls amongst active
UC
p-value p-value p-value Fold change p-value Fold change p-value
miR-200b-3p 0.314 0.026 0.017 2.148 0.033 0.719 0.259
miR-451a >0.5 0.402 0.019 0.661 0.155 1.662 0.054
miR-27b-3p 0.082 0.036 0.025 0.645 0.016 1.062 >0.5
miR-155-5p >0.5 >0.5 0.089 1.330 0.336 0.678 0.142
miR-19a-3p 0.280 0.057 0.323 1.021 >0.5 1.590 0.132
miR-30b-5p 0.116 0.062 0.347 1.116 >0.5 1.525 0.070
miR-30e-5p 0.405 0.278 0.408 0.999 >0.5 0.715 0.222
miR-21-5p >0.5 0.092 >0.5 0.977 >0.5 0.895 >0.5
https://doi.org/10.1371/journal.pone.0173664.t003
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miRNA in situ hybridization
Associations between miR-200b-3p and UC-DYS detected in the array and validation cohort
were further investigated using miRNA ISH techniques on archival FFPE blocks. To determine
whether miR-200b-3p was linked to CRC progression in UC patients in situ analysis was per-
formed on a series of FFPE specimens from UC controls and from UC patients with confirmed
UC-DYS and UC-adenocarcinomas; miR-21 levels were analysed in serial sections of a subset
of blocks as a positive control for staining.[27] Representative images are shown in Fig 3. Dis-
crete miR-200b-3p staining was identified in the epithelial cells of controls, UC-DYS and UC-
adenocarcinomas. In general, the strength of staining increased from UC controls through to
UC-adenocarcinomas (Fig 3). By comparison, miR-21 was more robustly expressed and
Fig 2. qPCR validation of miRNAs associated with ulcerative colitis-dysplasia. qPCR validation of
miRNAs associated with UC-DYS. (A-D) qPCR analysis of miR-200b-3p, miR-27b-3p, miR-451a and miR-21-
5p expression levels, in an expanded validation UC cohort. Significant difference were determined by two-
ANOVA and the data are presented as a two-way diamond mean comparison plot. The horizontal dashed line
represents the overall mean. The line through the centre of each diamond corresponds to the individual
groups mean. The top and bottom diamond vertices indicate the respective upper and lower 95% confidence
limits of the group means.
https://doi.org/10.1371/journal.pone.0173664.g002
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localised to the stroma of UC adenocarcinomas (Fig 3). No positive staining was observed in
sections incubated with a scrambled negative control probe.
Identification of miR-200b-3p targets in UC-dysplasia
By interrogating the gene signatures from cDNA microarray analysis of UC patients with neo-
plasia (UCN) compared to UC patients,[26] we found 129 mRNAs that were downregulated,
corresponding to 76 genes (S4 Table). Since an increase in miRNA levels would result in
mRNA downregulation, we investigated whether the reduced expression of these genes is a
result of the miRNA action. Among the 76 down-regulated genes, one gene, INO80D, was
among the targets of miR-200b-3p obtained by miRTarBase (S5 Table), a database of experi-
mentally confirmed miRNA targets. INO80D is a regulatory component of the chromatin
remodelling INO80 complex, which is involved in transcriptional regulation, DNA replication
and probably DNA repair. We expanded our search to target genes that are predicted by bioin-
formatics algorithms based on the miRNA seed sequence. Five downregulated genes (INO80D,
SHROOM1,HMBOX1, SLC4A4 and PLEKHA6) were among the targets predicted bioinforma-
tically by TargetScan (S6 Table), while six genes (PPARA, SHROOM1, SMIM5,HMBOX1,
ANK3,KMT2C) were predicted by miRDB (S7 Table). Among these genes, KMT2C is a lysine
methyltransferase found to be associated with colorectal cancer as well as acute myeloid leuke-
mia.[28,29] KMT2C has also been implicated in gastric cancer and could be useful as a marker
of prognosis.[30] Table 4 summarises these results.
Analysis of serum miRNA profiles in dysplasia and controls
MiRNAs are also present in the serum, where there is the potential to exploit them as non-
invasive biomarkers of dysplasia. Hence, we sought to determine serum miRNA levels in
UC-DYS patients (n = 8) and UC controls (n = 10). Levels of miRNA in the serum were
assessed by qPCR array (Exiqon) and the normalised data were analysed using SAM software
Fig 3. Localisation of miR-200b-3p in ulcerative colitis-dysplasia and adenocarcinomas Representative
images of miR-200b-3p staining are shown for UC controls, UC-dysplasia and UC-adenocarcinoma. A
pink counterstain (nuclear fast red) is used to visualise the section, and purple staining indicates positive miRNA
staining. In a serial section from the UC-adenocarcinoma, miR-21 staining is shown alongside miR-200b-3p to
demonstrate the difference in cellular localisation of these miRNA in the gut.
https://doi.org/10.1371/journal.pone.0173664.g003
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as per the tissue arrays (with a cut-off of a fold change>2 set). However, no significantly
altered miRNAs in the serum of UC-DYS patients relative to UC controls were identified; with
an adjusted cut-off of a fold change>1.5 there were 4 miRNAs were identified: miR-423-3p
and miR-28-5p were present at higher levels, whereas serum levels of miR-150-5p, miR-32-5p
were reduced in UC-DYS (Fig 4). However, with a false discovery rate of 1.12 a cut-off of a
fold change> 1.5 is not stringent enough, and these miRNAs are highly likely to represent
false positives.
Discussion
In this study miRNA profiles associated with dysplastic lesions in UC patients were investi-
gated. Multivariate analysis demonstrated good separation of UC-DYS from UC controls,
Table 4. Targets of miR-200b-3p that are downregulated in UC patients with neoplasia compared to UC patients.
Gene miRNA-target
database
Function (Based on Uniprot)
INO80D miRTarBase,
TargetScan
Putative regulatory component of the chromatin remodeling INO80 complex which is involved in transcriptional
regulation, DNA replication and probably DNA repair.
SHROOM1 TargetScan, miRDB May be involved in the assembly of microtubule arrays during cell elongation.
HMBOX1 TargetScan, miRDB Transcription factor. Isoform 1 acts as a transcriptional repressor. Isoform 4 has very low activity as a transcriptional
repressor.
SLC4A4 TargetScan Electrogenic sodium/bicarbonate cotransporter with a Na(+):HCO3(-) stoichiometry varying from 1:2 to 1:3. May
regulate bicarbonate influx/efflux at the basolateral membrane of cells and regulate intracellular pH.
PLEKHA6 TargetScan Pleckstrin homology domain-containing family A member 6
PPARA miRDB Ligand-activated transcription factor. Key regulator of lipid metabolism. Functions as transcription activator for the
ACOX1 and P450 genes.
SMIM5 miRDB Small Integral Membrane Protein 5
ANK3 miRDB In skeletal muscle, required for costamere localization of DMD and betaDAG1 (By similarity). Membrane-
cytoskeleton linker. May participate in the maintenance/targeting of ion channels and cell adhesion molecules at the
nodes of Ranvier and axonal initial segments. Regulates KCNA1 channel activity in function of dietary Mg(2+) levels,
and thereby contributes to the regulation of renal Mg(2+) reabsorption
KMT2C miRDB Histone methyltransferase. Methylates Lys-4 of histone H3. H3 Lys-4 methylation represents a specific tag for
epigenetic transcriptional activation. Central component of the MLL2/3 complex, a coactivator complex of nuclear
receptors, involved in transcriptional coactivation. KMT2C/MLL3 may be a catalytic subunit of this complex. May be
involved in leukemogenesis and developmental disorder
https://doi.org/10.1371/journal.pone.0173664.t004
Fig 4. Serum miRNA levels in UC dysplasia and UC controls. Serum levels of miRNAs with a fold change
>1.5 in UC patients with dysplasia compared to UC controls are shown. Data are presented as a box and
whiskers plot. Differences in the levels of these miRNAs in serum did not reach the statistical significance
threshold.
https://doi.org/10.1371/journal.pone.0173664.g004
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indicating a shift in miRNA expression profiles in tissue from UC-DYS. However, there was a
larger degree of variance between the UC-DYS samples with respect to their miRNA profiles,
highlighting the inherent heterogeneity of this group. For future studies it will be important to
understand the significance of the profile heterogeneity for UC-DYS progression, as not all
LGD will progress to HGD and/or CRC [9–15]. Whether this heterogeneity in miRNA profiles
could be exploited to identify the dysplastic lesion most likely to progress remains to be seen.
Encouragingly, from a molecular biomarker perspective, the observed changes in miRNA
expression in this study appeared specific to UC-DYS because similar changes were not
observed in UC-IPs. In fact, the miRNA profiles of UC-IPs were largely indistinguishable from
UC controls, suggesting that these lesions might not have pre-malignant potential that could
be linked to miRNAs expression changes.
A number of differentially expressed miRNAs in UC-DYS that were identified in this study
have been previously linked to IBD-dysplasia,[20] providing independent validation of our
results. For example, Olaru and colleagues demonstrated broad increases in the miR-200 fam-
ily in IBD-dysplasia (both UC and CD patients) relative to chronically inflamed controls, a
finding that is in keeping with the up-regulation of miR-200b-3p reported here. While both
studies show that increased miR-200b-3p expression is a feature of UC-DYS, it is important to
note that in our study, miR-200b-3p was only upregulated in dysplastic lesions of patients in
clinical and histological remission, i.e. no inflammatory infiltrates. Inflammation supressed
miR-200b-3p and so in patients with ‘active’ disease there was no difference in miR-200b-3p
in our validation cohort. Surveillance colonoscopies are already indicated for patients in clini-
cal remission, our data would now indicate that the presence of inflammatory infiltrates in the
mucosa should also be considered when assessing the utility as a biomarker. The observation
that miR-200b-3p is supressed in patients with evidence of active disease is consistent with
reports that show a reduction in miR-200b in inflamed UC colon and reports that the reduced
expression of miR-200b in IBD patients is linked to epithelial mesenchymal transition (EMT).
[31,32] The effect of inflammation may be to down-regulate miR-200b-3p in other cell types
within the mucosa.
As this study focuses predominantly on the analysis of low-grade UC-DYS, it seems likely
that the observed up-regulation of the miR-200 family is a very early event in the UC-CRC
development pathway. The analysis of miR-200b-3p using miRNA-ISH techniques further
supports a functional role for this miRNA in development of UC-CRC as miR-200-3p is local-
ised to intestinal epithelial cells in UC patients consistent with its known role in determining
epithelial cell fate.[18,33] Notably, the strength of miR-200b-3p staining increased at each
stage of malignancy, UC-DYS and UC-CRC. In line with the findings of this study, increased
expression of miR-200b-3p in colon cancer cells in vitro has previously been reported,[34] and
high expression of miR-200b-3p observed in sporadic colorectal tumours compared to adja-
cent mucosa.[35]
Previous studies have identified altered mRNA signatures associated with dysplasia in UC
that were progressively altered during neoplastic progression.[26] In this study we have utilised
this available data set and interrogated it for down-regulated genes with a miR-200b-3p bind-
ing site. This list included genes associated with chromatin remodelling and DNA transcrip-
tion (e.g. INO80D and KMT2C). The functional significance of the suppression of these genes
on the progression of UC-DYS is currently unknown. Little is known about the role of the
INO80D subunit. However, loss of function mutations in KMT2C, a histone lysine methyl-
transferase, have been identified in a number of cancers,[36] and colorectal cancer cell lines,
[37] pointing towards a tumour suppressor role. This is supported by the fact that KMT2C
knockout mouse model that developed ureter epithelial tumors.[38] Correlating miRNA and
mRNA expression data sets can give useful insights into the potential action of a miRNA in
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vivo and provide direction for future experimentation that can confirm whether, for example,
the suppression of 200b-3p targets in UC-DYS is a direct consequence of the up-regulation of
miR-200b-3p.
While there was good concordance between our study and the previous studies for IBD-
dysplasia and miR-200b-3p,[19] we were unable to fully validate the increase in miR-21-5p in
UC-DYS that was observed in the array and has previously been reported by Ludwig and col-
leges;[18] instead in the validation analysis this miRNA was much more strongly associated
with active inflammation as opposed to the presence of dysplasia, which is known to be an
independent risk factor for the development of UC DYS and UC CRC.[39] The link between
high miR-21-5p may therefore be highly dependent on the patients inflammatory status. Nev-
ertheless, high levels of miR-21 were observed using miRNA ISH techniques in UC-CRC; in
these tumours miR-21 was localised to the stroma and not epithelial cells, a finding which
contrasts with Ludwig et al,[18] but accords with Hedbäck et al.[40] The conflicting results
between studies for miR-21 localisation is likely a results of using different in situ hybridization
probes, this will need to resolved before a definitive answer on miR-21 localisation can be
given.
Unfortunately, reported differences in miR-31 in IBD-dysplasia,[19] could not be fully
interrogated because of its low expression levels in the samples analysed in this study. How-
ever, the only two samples from the array where miR-31 was detected above the background
threshold levels were dysplastic, which is consistent with the earlier reported increase in dys-
plasia in the literature. Our data suggest that up-regulation of miR-31 is not sufficiently consis-
tent across UC-DYS specimens for this miRNA to be a good biomarker candidate of LGD, as
the absence of its expression could lead to false negative diagnoses of dysplasia.
Attempts to identify a non-invasive serum biomarker of UC-DYS were also made, but no
significant differences in serum miRNA expression were observed. This was a novel analysis,
and the lack of statistical differences likely reflects the fact that any serum dysplasia signal will
be very weak given only a small proportion of cells in the gut are affected, and the serum
miRNA pool is derived from all cells in the body. Also, the current study may have been
underpowered to detect small differences in miRNA levels in the serum of UC-DYS patients.
However, it should be acknowledged that the rarity of the UC-DYS makes large population
biomarker studies extremely challenging. Nevertheless, we believe that the data from this study
can be used to inform future studies.
There are some limitations to our study. The estimated prevalence of LGD in UC is 15 cases
per 1000 patients per year in the UK. [41] Therefore significant numbers of patients need to be
screened to identify dysplasia specimens for analysis. To address this we recruited from ten
NHS trusts with major inflammatory bowel disease surveillance centres across the UK. Despite
this, a clear limitation of this study is the sample size, which reflects the low frequency of
UC-DYS, and the difficulty in obtaining sufficient specimens from well-phenotyped patients.
Independent validation is therefore an important step that requires adequate numbers. It is
therefore encouraging that several miRNAs identified here had been previously linked to IBD-
dysplasia, e.g. miR-200b-3p.[19] For future studies a standardized miRNA analysis pipeline
should be implemented to facilitate direct cross-comparisons between studies, enabling pooling
of data and large population studies, as we have recommended in a recent review;[16] each of
the studies performed to date have used different miRNA profiling platforms and methods
(Table 5). The data from this study also highlight the need to control for heterogeneity within
the UC-DYS group, as potential confounding variables include the size of the field of dysplasia,
the extent of inflammation within a lesion, length of disease duration and patient’s medications.
Given the relatively advanced age of the UC-dysplasia cohort (median 73-years), there is an
increased risk of sporadic CRC and neoplasias, which may not be directly attributed to the
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underlying presence of UC. These confounders are inherently difficult to control for in small
populations, although this is essential if more accurate biomarkers of progression are to be
developed, as dysplasia is not a single homogenous group.
In summary, CRC is a life-threatening complication of UC, and surveillance programmes
use regular colonoscopy to identify early pre-cancerous lesions (dysplasia) and guide patient
care. However, we know very little about the molecular changes that occur in these dysplastic
lesions and rates of CRC occurrence in patients with confirmed LGD vary widely. A better
understanding of the underlying mechanisms of dysplasia may allow for more accurate identi-
fication of the lesions that harbour the highest risk of malignancy. In this study we have shown
that dysplasia is associated with alterations in the miRNA expression profiles and have demon-
strated localisation of this miRNA to epithelial cells in dysplastic lesions and in UC associated
CRCs. This study highlights increased expression of miR-200b-3p as a critical component of
UC-DYS and a relevant target for therapy.
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Study
Reference
Study size Detection methods Tissue
type
Comparisons made
Lewis et al UC controls & UC dysplasia (n = 10
and n = 7, respectively).
Untargetd microNOME-wide analysis: miRCURY
LNA™ microRNA Array (7th Gen), Exiqon
Fresh
frozen
UC control (active & inactive) Vs.
UC dysplasia
Olaru et al Inflamed IBD controls & IBD
dysplasia (n = 8, respectively)




Chronically active IBD Vs. IBD
dysplasia




Active UC Vs. UC dysplasi & Active
CD Vs. CD dysplasia
https://doi.org/10.1371/journal.pone.0173664.t005
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